EP Patent

EP4171232A1 — Modified release formulations of modified forms of trimetazidine

Assigned to Imbria Pharmaceuticals Inc · Expires 2023-05-03 · 3y expired

What this patent protects

The invention provides pharmaceutical compositions that contain modified release formulations of modified forms of trimetazidine, such as CV-8972. The compositions include an erodible polymer, such as hydroxypropyl methylcellulose (HPMC), that allows sustained release of the modi…

USPTO Abstract

The invention provides pharmaceutical compositions that contain modified release formulations of modified forms of trimetazidine, such as CV-8972. The compositions include an erodible polymer, such as hydroxypropyl methylcellulose (HPMC), that allows sustained release of the modified form of trimetazidine and it metabolic products in the body. The invention also provides methods of treating conditions, including angina and heart failure, using such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP4171232A1
Jurisdiction
EP
Classification
—
Expires
2023-05-03
Drug substance claim
No
Drug product claim
No
Assignee
Imbria Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.